Reply. We thank the authors of the letter for their thoughtful comments in response to our article. 1 We agree that centralized endoscopic reading represents an important advance in inflammatory bowel disease (IBD) clinical trials. Across studies in the IBD space in the past decade, the sample sizes used to achieve statistical significance in late phase clinical trials have been decreasing. As the authors of the letter have pointed out, this trend could be the result of the decrease in placebo response rates in IBD trials over this same time period.
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Although this trend could be attributable to the use of central reading to identify patients with active disease for study inclusion, other factors could be involved. For example, in the trial leading to the approval of vedolizumab for ulcerative colitis, 2 clinical remission rates were 16.9% in the active treatment group and 5.4% in the placebo treatment group. In the trial leading to the approval of vedolizumab for Crohn's disease, 3 clinical remission rates were 14.5% in the active treatment group and 6.8% in the placebo group. In UNITI-1, which led to the approval of ustekinumab for Crohn's disease, 4 clinical remission rates were 20.9% in the active treatment group and 7.3% in the placebo treatment group. A notable feature of all of these studies was the absence of central endoscopic reading as the basis for study entry. In the first 2 trials, 41% and 57.8% of patients, respectively, had failed 1 anti-tumor necrosis factor agent; in UNITI-1, 100% of patients had primary nonresponse to anti-tumor necrosis factor agents. In addition, across the 3 studies, patients were required to exhibit evidence of active disease by C-reactive protein, fecal calprotectin or a locally read sigmoidoscopy or colonoscopy. In a study examining the effects of central reading on mesalamine ulcerative colitis remission, retrospective application of central endoscopy resulted in only a 3.7% decrease in the placebo response rate, from 16.3% to 12.6%. These findings collectively suggest that the decreasing placebo rates in recent IBD clinical trials could at least be attributed, in part, to the inclusion of patients who were refractory to biologic therapies or who fulfilled more stringent criteria for active disease rather than use of central reading per se.
Furthermore, screen failure rates are as much a concern for the conduct of a clinical trial as the decrease in the number of patients needed to be randomized to demonstrate a treatment effect. Although actual numbers are not published, experience suggests that the screen failure rates in clinical trials now exceed 50% in ulcerative colitis and approach 70% in Crohn's disease. Although setting high bars for trial entry might decrease the sample sizes required for statistical significance, this strategy is counterproductive if suitable patients are more difficult to find, resulting in the exclusion of patients who could otherwise participate in these trials.
Finally, the absolute effect of more stringent criteria for study entry depends on the actual effects of these interventions on both the placebo and active treatment groups. One would be less excited by a decrease in placebo response rate if it were accompanied by a decrease in the active control group response or diminishing treatment effect. As pointed out by the authors of the letter, reductions in absolute drug efficacy rates in parallel with decreasing placebo rates are of concern.
We applaud the efforts of the authors of the letter to improve the efficiency of IBD clinical trials and thank them for their suggestions. However, many factors need to be considered before any single solution to the problem of enrollment in IBD clinical trials can be identified.
Population Difference and Disease Status Affect the Association Between Genetic Variants and Gene Expression
Dear Editors:
Colorectal cancer (CRC) is complex human disease. 1,2 Lu et al 3 performed a genome-wide association study by analyzing 22,775 CRC cases and 47,731 controls without cancer in the Asia Colorectal Cancer Consortium. They identified 14 novel CRC risk variants at the genome-wide significance level of P < 5.00 -08 in Asian populations. 3 Lu et al further evaluated the association of these variants with CRC risk in European populations. 3 They found that 6 of 14 novel CRC risk variants (rs113569514, rs6584283, rs2730985, rs1886450, rs4341754, and rs1078643) were also significantly associated with CRC risk in European populations with the same as in Asian populations. 3 Lu et al also performed an expression quantitative trait loci (eQTLs) analysis using 2 eQTLs datasets, including tumor adjacent normal colon tissue from East Asian CRC cases (n ¼ 133), 3 and transverse colon tissue (n ¼ 246) in the Genotype-Tissue Expression (GTEx) database. 3 Lu et al identified 21 and 37 significant correlations (P < 0.05) in East Asian and GTEx datasets, respectively. 3 However, only 2 CRC risk variants-rs1476570 and rs3830041-had the same association direction on gene expression in both datasets. Lu et al did not explain why most CRC risk variants had different association direction on gene expression in East Asian and GTEx datasets. Hence, this concern prompted us to investigate their findings further.
We think that the effects of genetic variants on gene expression may be population and/or disease specific. Hence, 2 possibilities may cause different association between CRC risk variants and the expression of nearby genes in human colon tissue. The first possibility is the population difference in Asian populations and European populations. It is reported that the majority of individuals in the GTEx cohort are of European ancestry. 4 Meanwhile, Lu et al have hypothesized and demonstrated the differences in genetic architecture between Asian and European populations. 3 There is considerable heterogeneity of 12 CRC risk variants in East Asian and European populations, as determined by Cochran's Q test and I 2 statistic. 3 The second possibility is the disease status, which may have a significant effect on gene expression. 5, 6 The East Asian eQTLs dataset was based on tumor adjacent normal colon tissue from CRC cases. The GTEx dataset was based on transverse colon tissue from non-CRC cases, but not healthy individuals. The deaths of donors in GTEx consisted of traumatic injury and cerebrovascular, heart, liver, renal, respiratory, and neurologic diseases. 4 Hence, eQTLs analysis using disease samples should take into consideration the effect of disease status, as in recent studies. 5, 7 To further confirm this view, we evaluated the association between these CRC risk variants and the expression of nearby genes using a public available eQTLs dataset. 8 This eQTLs dataset included 97 colon tumor tissue samples, 97 paired adjacent normal colon mucosa tissue samples, and 47 healthy colon mucosa tissue samples. 8 The CRC cases are from University Hospital of Bellvitge in Barcelona between January 1996 and December 2000. 8 The healthy colon mucosa samples were obtained during colonoscopy between February and May 2010. 8 A Pearson correlation analysis was used to perform the eQTLs analysis by adjusting for age, sex, and tumor location. 8 The significance threshold was defined to be P < .05.
The results supported our hypothesis. The population difference could affect the association between CRC risk variants and gene expression. In the same adjacent normal tissue, eQTLs analysis in East Asian populations identified 7 significant correlations between 5 CRC risk variants and the expression of 7 genes. However, these correlations were not successfully replicated in European populations, even for the rs113569514, rs1886450, and rs1078643 variants, which were significantly associated with CRC risk with the same direction in Asian populations and European populations (Table 1) . 3 Meanwhile, the disease status could also affect the association between CRC risk variants and gene expression. In the same population, rs3830041 and rs1078643 could significantly regulate the expression of PRRC2A and rs1078643 in AN, adjacent normal tissue; CT, colon tumor tissue; HC, healthy colon tissue; TC, transverse colon tissue. The significance threshold was defined to be P < .05. a rs1078643 is not available, we selected its proxy rs1550656 (r 2 ¼ 0.62 and D' ¼ 1).
healthy colon tissue (P < .05). However, these correlations were not successfully replicated in colon tumor tissue and adjacent normal tissue (Table 1 ). In addition, among 8 significant correlations identified in GTEx with kinds of cause of death, only 1 correlation was significant in healthy colon tissue, even thought there was no significant correlation in colon tumor tissue and adjacent normal tissue (Table 1) .
In summary, we highlight that population difference and disease status could affect the association between CRC risk variants and gene expression. Hence, both factors should be taken into consideration in eQTLs analysis to detect the exact association.
